ListarDAAPC-Artículos, capítulos... por tema "PD-L1"
Mostrando ítems 1-3 de 3
-
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
(MDPI, 2020)Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year ... -
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
(MDPI, 2021)A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the ... -
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing
(MDPI, 2021)Immuno-oncology (IO) agents (anti–programmed cell death 1 (PD-1) and anti–programmed cell death-ligand 1 (PD-L1)) are approved as first- and second-line treatments for metastatic UC. PD-L1 expression levels in UC tumors ...